Canada markets open in 23 minutes

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5500-0.0300 (-5.17%)
At close: 03:59PM EDT
Full screen
Previous Close0.5800
Open0.6000
Bid0.5500 x N/A
Ask0.5900 x N/A
Day's Range0.5500 - 0.6000
52 Week Range0.3200 - 2.5000
Volume97,500
Avg. Volume54,853
Market Cap18.149M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research

    Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been awarded a seven-figure, five-year grant from the Canadian Institutes of Health Research (CIHR). The grant entitled "Muscle Stem Cell Function in Duch

  • Newsfile

    Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications

    Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has had new research published in the most recent edition of Nature Communications. The article, titled "GLI3 regulates muscle stem cell entry into GAlert and

  • Newsfile

    Satellos Bioscience Inc. Announces Proposed Offering of Units

    Toronto, Ontario--(Newsfile Corp. - July 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units of the Company ("Units"), co